
The Danish company Azanta is now entering the Middle Eastern market through a collaboration deal with Israeli company Lavi. The deal stipulates that Lavi will have the exclusive distribution of the two Azanta drugs Nimoral and Zybrestat in Israel.
“This deal marks our entry into the Middle East, and it reflects our strategy to become an industry leader by making innovative treatments available to patients on international markets,” says CEO Claus Møller in a press release.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app